GE HealthCare shares were lower by roughly 3% in U.S. trading, extending a pullback as the market reacted to a new price-target reduction from a major sell-side firm. Evercore ISI lowered its price target on GEHC to $85 from $98 while maintaining an Outperform rating, a combination that often signals continued fundamental confidence but a reset to near-term valuation and expectation levels. (streetinsider.com)

A price-target cut can weigh on momentum-heavy healthcare equipment names because it compresses the implied upside used by incremental buyers, even when the rating stays positive. With GEHC trading around the low-$70s, the revised target still implies upside, but the direction of estimate/valuation revisions can drive short-term selling—particularly for investors positioning ahead of upcoming catalysts and quarterly updates. (gurufocus.com)

Investors will be watching for follow-through in additional target changes across the Street and any company-specific updates that could reframe near-term earnings power and product demand. Separately, recent regulatory and product headlines in the imaging software ecosystem—such as FDA-classified recall activity involving GE HealthCare’s Centricity Universal Viewer tied to cybersecurity concerns—remain an overhang investors may re-price quickly if they see elevated remediation costs or customer disruption. (hipaajournal.com)